Skip to main content
TrialFinder
TrialFinder is for informational purposes only and does not provide medical advice. Always talk to your doctor about whether a trial is right for you.
RECRUITINGINTERVENTIONAL

CAR-T Immunomonitoring in Multiple Myeloma (CART I5M)

CAR-T Immunomonitoring in Multiple Myeloma

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.

About This Trial

Multiple myeloma patients can be treated with cell therapy, which uses some of their own modified white blood cells (T lymphocytes) to target a protein (BCMA, or B-cell maturation antigen) found on the surface of the myeloma plasma cells. These modified T lymphocytes are called CAR T cells (chimeric antigen receptor T cells). The long-term persistence of these modified lymphocytes, or CAR-BCMA, is a recognized indicator of a good response to treatment. This research aims to study certain markers related to CAR-BCMA cell persistence. This research will be carried out in collaboration with the Laboratory of Ischemia Reperfusion, Metabolism and Sterile Inflammation in Transplantation (IRMETIST) INSERM unit U1313, located at the University of Poitiers. The proposed project will contribute to better patient care in the field of oncology, by identifying immunological cellular markers predictive of an effective response to anti-cancer treatments and/or immunotherapeutic targeting.

Who May Be Eligible (Plain English)

Who May Qualify: - Patient aged 18 and over - Patient with Multiple Myeloma according to international recommendations, - Patient about to receive CAR-T cell therapy in accordance with the rules and authorizations in France. Who Should NOT Join This Trial: - Patients with severely impaired physical and/or psychological health, which, according to the investigator, may affect the participant's compliance with the study. - Simultaneous participation in another study with an ongoing exclusion period. - Individuals receiving enhanced protection, namely minors, pregnant and/or breastfeeding women, individuals deprived of their liberty by a judicial or administrative decision, individuals residing in a healthcare or social care facility, adults under legal guardianship, and finally, patients in emergency situations Always talk to your doctor about whether this trial is right for you.

Original Eligibility Criteria

View original clinical language
Inclusion Criteria: * Patient aged 18 and over * Patient with Multiple Myeloma according to international recommendations, * Patient about to receive CAR-T cell therapy in accordance with the rules and authorizations in France. Exclusion Criteria: * Patients with severely impaired physical and/or psychological health, which, according to the investigator, may affect the participant's compliance with the study. * Simultaneous participation in another study with an ongoing exclusion period. * Individuals receiving enhanced protection, namely minors, pregnant and/or breastfeeding women, individuals deprived of their liberty by a judicial or administrative decision, individuals residing in a healthcare or social care facility, adults under legal guardianship, and finally, patients in emergency situations

Treatments Being Tested

OTHER

Additional Bone Marrow cells and blood sampling

Additional Bone Marrow cells and blood sampling

Locations (1)

Chu de Poitiers
Poitiers, France